Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Hypersensitivity Reaction

Free Subscription Articles published in Br J Dermatol Retrieve available abstracts of 204 articles: HTML format

Single Articles

April 2024
1. SIMPSON EL, Eckert L, Gadkari A, Brown TM, et al
   Evaluating the clinical utility of the Atopic Dermatitis Control Tool: measurement properties and agreement between patients' responses and clinicians' impressions of atopic dermatitis control.
   Br J Dermatol. 2024 Apr 9:ljae056. doi: 10.1093.
   PubMed    
   
   
   March 2024
2. SANDER N, Stolzl D, Fonfara M, Hartmann J, et al
   Blockade of IL-13 signaling improves skin barrier function and biology in patients with moderate to severe atopic dermatitis.
   Br J Dermatol. 2024 Mar 26:ljae138. doi: 10.1093.
   PubMed     Abstract available
   
   
   
3. BENTZ P, Weisshaar E
   Biomarkers as key concepts in managing atopic dermatitis and psoriasis: Unlocking new ways of care for patient suffering from chronic hand dermatoses.
   Br J Dermatol. 2024 Mar 26:ljae127. doi: 10.1093.
   PubMed    
   
   
   
4. 
   Correction to: Circulating biomarkers are associated with disease severity of chronic hand eczema and atopic dermatitis.
   Br J Dermatol. 2024 Mar 22:ljae112. doi: 10.1093.
   PubMed    
   
   
   
5. 
   The relationship between paediatric eczema and cognition.
   Br J Dermatol. 2024;190:e41.
   PubMed    
   
   
   
6. 
   A guide to using the core outcome set for eczema.
   Br J Dermatol. 2024;190:e44.
   PubMed    
   
   
   
7. NIELSEN W, Drucker AM
   The need and benefit of the Harmonising Outcome Measures for Eczema user's guide.
   Br J Dermatol. 2024;190:462-463.
   PubMed    
   
   
   
8. 
   Correction to: Malignancy risk in patients with atopic dermatitis: a population-based cohort study.
   Br J Dermatol. 2024 Mar 12:ljae093. doi: 10.1093.
   PubMed    
   
   
   
9. CHEN GF, Xu S, White MA, Cohen JM, et al
   Association between atopic dermatitis and eating disorders: a cross-sectional study in the All of Us Research Program.
   Br J Dermatol. 2024 Mar 11:ljae103. doi: 10.1093.
   PubMed    
   
   
   February 2024
10. RAMESSUR R, Dand N, Langan SM, Saklatvala J, et al
    Defining disease severity in atopic dermatitis and psoriasis for the application to biomarker research- an inter-disciplinary perspective.
    Br J Dermatol. 2024 Feb 29:ljae080. doi: 10.1093.
    PubMed     Abstract available
    
    
    
11. 
    A clinical trial investigating if antibacterial therapeutic clothing could improve atopic dermatitis.
    Br J Dermatol. 2024;190:e29.
    PubMed    
    
    
    
12. BREHON A, Bensefa-Colas L, D'Andrea C, Jeziorski E, et al
    Guidelines for cold urticaria management established by the Centre of Evidence of Dermatology and the Urticaria Group of the French Society of Dermatology.
    Br J Dermatol. 2024;190:445-447.
    PubMed    
    
    
    
13. KOBYLETZKI LBV, Svensson A
    Long term outcome measures of atopic dermatitis gain importance: a validation study filling a research gap.
    Br J Dermatol. 2024 Feb 5:ljae049. doi: 10.1093.
    PubMed    
    
    
    January 2024
14. DAINTY KN, Thibau IJC, Amog K, Drucker AM, et al
    Towards a patient-centered definition for atopic dermatitis flare: A qualitative study among adults with atopic dermatitis.
    Br J Dermatol. 2024 Jan 30:ljae037. doi: 10.1093.
    PubMed     Abstract available
    
    
    
15. 
    Comparing systemic treatments for eczema.
    Br J Dermatol. 2024;190:e16.
    PubMed    
    
    
    
16. 
    A study using machine learning to help identify subgroups of adults with atopic dermatitis.
    Br J Dermatol. 2024;190:e19.
    PubMed    
    
    
    
17. 
    A decreasing trend of atopic dermatitis among children in Sweden.
    Br J Dermatol. 2024;190:e17.
    PubMed    
    
    
    
18. SOEGIHARTO R, Westmeijer M, Boekema-Bakker N, Groenewegen IAM, et al
    Prevalence of chronic urticaria and healthcare usage of patients with the condition in primary care: a population-based study in the Netherlands.
    Br J Dermatol. 2024;190:287-289.
    PubMed    
    
    
    
19. FUNCH AB, Glindvad Ahlstrom M, Johansen JD, Geisler C, et al
    Neutrophil Infiltration in Allergic Contact Dermatitis to Nickel.
    Br J Dermatol. 2024 Jan 4:ljad499. doi: 10.1093.
    PubMed    
    
    
    
20. YOO LJH, Stefanovic N, Watchorn RE
    Atopic Dermatitis and Autism: Tactile Hypersensitivity Impeding on Topical Therapy Use.
    Br J Dermatol. 2024 Jan 4:ljae005. doi: 10.1093.
    PubMed    
    
    
    
21. SMITH KA, Hiyoshi A, Vingeliene S, von Kobyletzki L, et al
    Atopic dermatitis and cognitive function: a sibling comparison study among males in Sweden.
    Br J Dermatol. 2024 Jan 3:ljae004. doi: 10.1093.
    PubMed    
    
    
    December 2023
22. JOHNSON C, Smith P, Haran K, Kranyak A, et al
    Comment on 'Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD study'.
    Br J Dermatol. 2023 Dec 27:ljad529. doi: 10.1093.
    PubMed    
    
    
    
23. 
    Nemolizumab reduces itch and improves other signs of atopic dermatitis in children aged 6-12 years.
    Br J Dermatol. 2023;190:e2.
    PubMed    
    
    
    
24. 
    Greater understanding about differences in the long-term course of eczema and their risk factors in children.
    Br J Dermatol. 2023;190:e5.
    PubMed    
    
    
    
25. 
    A study about how many people around the world have atopic dermatitis.
    Br J Dermatol. 2023;190:e6.
    PubMed    
    
    
    
26. 
    The role of enhancers in eczema and psoriasis.
    Br J Dermatol. 2023;190:e1.
    PubMed    
    
    
    
27. TIERNEY E, Evans P, Broderick V, Wynn R, et al
    Successful response to dupilumab in a refractory case of atopic dermatitis-like chronic cutaneous graft-versus-host disease.
    Br J Dermatol. 2023 Dec 20:ljad526. doi: 10.1093.
    PubMed    
    
    
    
28. FORKEL S, Schubert S, Corvin L, Heine G, et al
    Contact allergies to dental materials in patients.
    Br J Dermatol. 2023 Dec 20:ljad525. doi: 10.1093.
    PubMed     Abstract available
    
    
    
29. THOMAS KS, Howells L, Leshem YA, Simpson EL, et al
    How to use the HOME Core Outcome Set for atopic dermatitis trials - a users' guide.
    Br J Dermatol. 2023 Dec 20:ljad497. doi: 10.1093.
    PubMed     Abstract available
    
    
    
30. ABDI P, Haq Z, Diaz MJ, Maibach HI, et al
    Infectious disease among adults with allergic contact dermatitis: A propensity score-matched case-control study.
    Br J Dermatol. 2023 Dec 19:ljad504. doi: 10.1093.
    PubMed    
    
    
    
31. SOCKLER PG, Hooper SR, Abuabara K, Ma EZ, et al
    Atopic dermatitis, cognitive function, and psychiatric comorbidities across early childhood and adolescence in a population-based UK birth cohort.
    Br J Dermatol. 2023 Dec 7:ljad486. doi: 10.1093.
    PubMed     Abstract available
    
    
    
32. ISKANDAR IYK, Gawkrodger DJ, Gittins M, Byrne L, et al
    Trends in occupational and work-related contact dermatitis attributed to nickel, chromium and cobalt in the UK: findings from The Health and Occupation Research network 1996-2019.
    Br J Dermatol. 2023 Dec 7:ljad488. doi: 10.1093.
    PubMed     Abstract available
    
    
    
33. WEIDINGER S, Simpson EL, Silverberg JI, Barbarot S, et al
    Burden of Atopic Dermatitis in Pediatric Patients: An International Cross-sectional Study.
    Br J Dermatol. 2023 Dec 4:ljad449. doi: 10.1093.
    PubMed     Abstract available
    
    
    November 2023
34. YU J
    Are perinatal antibiotics responsible for atopic dermatitis? The Debate Rages On.
    Br J Dermatol. 2023 Nov 30:ljad477. doi: 10.1093.
    PubMed    
    
    
    
35. KIM M, Choi Y, Lee M, Kang J, et al
    Maternal SARS-CoV-2 infection during pregnancy and subsequent risk of atopic dermatitis in offspring: a nationwide birth cohort study in South Korea.
    Br J Dermatol. 2023 Nov 30:ljad478. doi: 10.1093.
    PubMed    
    
    
    
36. CAZZANIGA S, Simon D
    Decoding Atopic Dermatitis: Unveiling Phenotypes Through Data-Driven Methods.
    Br J Dermatol. 2023 Nov 17:ljad453. doi: 10.1093.
    PubMed    
    
    
    
37. 
    Correction to: Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): a multicentre parallel group assessor-blinded clinical trial.
    Br J Dermatol. 2023 Nov 16:ljad442. doi: 10.1093.
    PubMed    
    
    
    
38. 
    Improved sleep in adults with atopic dermatitis using the treatment dupilumab.
    Br J Dermatol. 2023;189:e106.
    PubMed    
    
    
    
39. 
    A clinical trial in children and young people with severe eczema comparing methotrexate with ciclosporin.
    Br J Dermatol. 2023;189:e105.
    PubMed    
    
    
    
40. 
    A study about the presence of Staphylococcus aureus growth at birth and at 2 months of age in children who developed atopic dermatitis in the first 2 years of life.
    Br J Dermatol. 2023;189:e107.
    PubMed    
    
    
    
41. CHERREZ-OJEDA I, Thomsen SF, Gimenez-Arnau A
    Alexithymia prevalence in individuals with chronic urticaria and its association with illness severity and therapeutic profile.
    Br J Dermatol. 2023;189:766-767.
    PubMed    
    
    
    
42. WAN J
    Changes in the epidemiology of atopic dermatitis: putting them into context.
    Br J Dermatol. 2023 Nov 11:ljad443. doi: 10.1093.
    PubMed    
    
    
    
43. YOSIPOVITCH G, Lio PA, Rosmarin D, Serra-Baldrich E, et al
    Lebrikizumab improved itch and reduced the extent of itch interference on sleep in patients with moderate-to-severe atopic dermatitis: two randomized, placebo-controlled, phase III trials.
    Br J Dermatol. 2023 Nov 6:ljad435. doi: 10.1093.
    PubMed    
    
    
    
44. RAGAMIN A, Schappin R, de Graaf M, Tupker RA, et al
    The effectiveness of antibacterial therapeutic clothing compared with non-antibacterial therapeutic clothing in patients with moderate-to-severe atopic dermatitis: A randomized controlled, observer-blind pragmatic trial (ABC trial).
    Br J Dermatol. 2023 Nov 4:ljad437. doi: 10.1093.
    PubMed     Abstract available
    
    
    
45. SHIMON SV, Desai K, Miteva M, Nadji M, et al
    High Expression of Interleukin-17A in Cutaneous Sarcoidosis.
    Br J Dermatol. 2023 Nov 4:ljad438. doi: 10.1093.
    PubMed    
    
    
    
46. HAIDER S, Granell R, Curtin JA, Holloway JW, et al
    Identification of eczema clusters and their association with filaggrin and atopic comorbidities: analysis of five birth cohorts.
    Br J Dermatol. 2023 Nov 3:ljad326. doi: 10.1093.
    PubMed     Abstract available
    
    
    October 2023
47. CHIESA FUXENCH Z, Mitra N, Del Pozo D, Hoffstad O, et al
    In utero or early in life exposure to antibiotics and the risk of childhood atopic dermatitis, a population-based cohort study.
    Br J Dermatol. 2023 Oct 28:ljad428. doi: 10.1093.
    PubMed     Abstract available
    
    
    
48. 
    Lifetime burden of Stevens-Johnson syndrome/toxic epidermal necrolysis.
    Br J Dermatol. 2023;189:e92.
    PubMed    
    
    
    
49. 
    Safety and effectiveness of amlitelimab, a potential new treatment for atopic dermatitis: results of a clinical trial.
    Br J Dermatol. 2023;189:e90.
    PubMed    
    
    
    
50. 
    Greater understanding about interpreting the Recap of atopic eczema (RECAP) questionnaire.
    Br J Dermatol. 2023;189:e95.
    PubMed    
    
    
    
51. OFENLOCH RF
    Filling the gap: investigating the interpretability of the Recap of atopic eczema questionnaire.
    Br J Dermatol. 2023;189:506-507.
    PubMed    
    
    
    
52. INGEN-HOUSZ-ORO S
    Epidermal necrolysis: a chronic disease associated with loss-of-life expectancy and lifetime healthcare expenditure.
    Br J Dermatol. 2023;189:505-506.
    PubMed    
    
    
    
53. LIU Y, Li Q, Chu C, Zhou Y, et al
    Insights into Stevens-Johnson syndrome/toxic epidermal necrolysis lifetime burden: assessing life expectancy, healthcare costs and quality of life.
    Br J Dermatol. 2023;189:648.
    PubMed    
    
    
    
54. ZHANG J, Ragamin A, Romeijn GLE, Loman L, et al
    Validity, reliability, responsiveness and interpretability of the Recap of atopic eczema (RECAP) questionnaire.
    Br J Dermatol. 2023;189:578-587.
    PubMed     Abstract available
    
    
    
55. WELFRINGER-MORIN A, Bataille P, Drummond D, Bellon N, et al
    Comparison of idiopathic and drug-induced epidermal necrolysis in children.
    Br J Dermatol. 2023;189:631-633.
    PubMed    
    
    
    
56. NYMAND L, Nielsen ML, Vittrup I, Halling AS, et al
    Atopic dermatitis phenotypes based on cluster analysis of the Danish Skin Cohort.
    Br J Dermatol. 2023 Oct 18:ljad401. doi: 10.1093.
    PubMed     Abstract available
    
    
    
57. DRUCKER AM, Lam M, Elsawi R, Prieto-Merino D, et al
    Comparing binary efficacy outcomes for systemic immunomodulatory treatments for atopic dermatitis in a living systematic review and network meta-analysis.
    Br J Dermatol. 2023 Oct 13:ljad393. doi: 10.1093.
    PubMed     Abstract available
    
    
    September 2023
58. AF KLINTEBERG M, Winberg A, Andersson M, Ronmark E, et al
    Decreasing prevalence of atopic dermatitis among Swedish schoolchildren. Three repeated population-based surveys.
    Br J Dermatol. 2023 Sep 30:ljad370. doi: 10.1093.
    PubMed     Abstract available
    
    
    
59. 
    Correction to: TMEM232 promotes the inflammatory response in atopic dermatitis via the nuclear factor-kappaB and signal transducer and activator of transcription 3 signalling pathways.
    Br J Dermatol. 2023 Sep 23:ljad346. doi: 10.1093.
    PubMed    
    
    
    
60. FLOHR C, Rosala-Hallas A, Jones AP, Beattie P, et al
    Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): a multicentre, parallel group, assessor-blinded clinical trial.
    Br J Dermatol. 2023 Sep 19:ljad281. doi: 10.1093.
    PubMed     Abstract available
    
    
    
61. NAKAHARA T, Fujita H, Tajima Y, Arima K, et al
    Evaluating the usefulness of the Atopic Dermatitis Control Tool for assessing disease control among individuals with atopic dermatitis in Japan.
    Br J Dermatol. 2023 Sep 15:ljad344. doi: 10.1093.
    PubMed    
    
    
    
62. 
    The risk of deep-vein blood clots in people with atopic dermatitis (eczema).
    Br J Dermatol. 2023;189:e75.
    PubMed    
    
    
    
63. 
    A review of major adverse cardiovascular events in patients with atopic dermatitis treated with oral Janus kinase inhibitors.
    Br J Dermatol. 2023;189:e69.
    PubMed    
    
    
    
64. VOORBERG AN, Kamphuis E, Christoffers WA, Schuttelaar MLA, et al
    Efficacy and safety of dupilumab in patients with severe chronic hand eczema with inadequate response or intolerance to alitretinoin: a randomized, double-blind, placebo-controlled phase IIb proof-of-concept study.
    Br J Dermatol. 2023;189:400-409.
    PubMed     Abstract available
    
    
    
65. TIAN J, Zhang D, Yang Y, Huang Y, et al
    The global epidemiology of atopic dermatitis: a comprehensive systematic analysis and modelling study.
    Br J Dermatol. 2023 Sep 14:ljad339. doi: 10.1093.
    PubMed     Abstract available
    
    
    
66. FUXENCH ZCC, Wan J, Wang S, Syed MN, et al
    Atopic Dermatitis and risk for headache disorders and migraines: a population-based cohort study in children and adults from the United Kingdom.
    Br J Dermatol. 2023 Sep 6:ljad325. doi: 10.1093.
    PubMed    
    
    
    
67. LLOYD-LAVERY A
    Nemolizumab to target the itch-scratch cycle in paediatric atopic dermatitis.
    Br J Dermatol. 2023 Sep 2:ljad319. doi: 10.1093.
    PubMed    
    
    
    
68. SUI JY, Eichenfield DZ, Sun BK
    The Role of Enhancers in Psoriasis and Atopic Dermatitis.
    Br J Dermatol. 2023 Sep 2:ljad321. doi: 10.1093.
    PubMed     Abstract available
    
    
    
69. LEE EY, Drucker AM
    A detailed evaluation of dupilumab's effect on sleep in adults with atopic dermatitis.
    Br J Dermatol. 2023 Sep 2:ljad320. doi: 10.1093.
    PubMed    
    
    
    August 2023
70. 
    The impact of a dose reduction of dupilumab when treating people with well-controlled atopic dermatitis.
    Br J Dermatol. 2023;189:e68.
    PubMed    
    
    
    
71. ROESNER LM, Wittmann M
    Hand eczema leaves systemic traces.
    Br J Dermatol. 2023;189:e56-e59.
    PubMed    
    
    
    
72. ARENTS BWM, van Zuuren EJ, Hughes O, Fedorowicz Z, et al
    The future is now: the Global Atopic Dermatitis Atlas (GADA).
    Br J Dermatol. 2023 Aug 11:ljad286. doi: 10.1093.
    PubMed    
    
    
    
73. MEROLA JF, Chiou AS, During E, Costanzo A, et al
    Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase 4 randomized double-blinded placebo-controlled DUPISTAD study.
    Br J Dermatol. 2023 Aug 10:ljad284. doi: 10.1093.
    PubMed     Abstract available
    
    
    July 2023
74. IGARASHI A, Katsunuma T, Matsumura T, Komazaki H, et al
    Efficacy and safety of nemolizumab in paediatric patients aged 6-12 years with atopic dermatitis with moderate-to-severe pruritus: Results from a phase III, randomised, double-blind, placebo-controlled, multicentre study.
    Br J Dermatol. 2023 Jul 31:ljad268. doi: 10.1093.
    PubMed     Abstract available
    
    
    
75. RINNOV MR, Gerner T, Halling AS, Liljendahl MS, et al
    The association between S. aureus colonization on cheek skin at 2 months and subsequent atopic dermatitis in a prospective birth cohort.
    Br J Dermatol. 2023 Jul 22:ljad249. doi: 10.1093.
    PubMed     Abstract available
    
    
    
76. WEIDINGER S, Bieber T, Cork MJ, Reich A, et al
    Safety and efficacy of amlitelimab, a fully human, non-depleting, non-cytotoxic anti-OX40Ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomised placebo-controlled trial.
    Br J Dermatol. 2023 Jul 18:ljad240. doi: 10.1093.
    PubMed     Abstract available
    
    
    
77. 
    Benefits of treatment with dupilumab for children aged 6-11 years with severe atopic dermatitis.
    Br J Dermatol. 2023;189:e39.
    PubMed    
    
    
    
78. LAM M, Spuls PI, Leshem YA, Gerbens LAA, et al
    Reporting of Harmonising Outcome Measures for Eczema (HOME) Core Outcome Set Instruments in randomized clinical trials for systemic treatments in Atopic Dermatitis.
    Br J Dermatol. 2023 Jul 12:ljad237. doi: 10.1093.
    PubMed    
    
    
    
79. CHIU YM, Chiu HY
    Lifetime risk, life expectancy, loss-of-life expectancy, and lifetime healthcare expenditure for Stevens-Johnson syndrome/toxic epidermal necrolysis in Taiwan: follow-up of a nationwide cohort from 2008 to 2019.
    Br J Dermatol. 2023 Jul 10:ljad234. doi: 10.1093.
    PubMed     Abstract available
    
    
    
80. 
    Better understand about circulating biomarkers and disease severity of chronic hand eczema and atopic dermatitis.
    Br J Dermatol. 2023;189:e34.
    PubMed    
    
    
    
81. WAN J, Shin DB, Syed MN, Abuabara K, et al
    Malignancy risk in patients with atopic dermatitis: a population-based cohort study.
    Br J Dermatol. 2023;189:53-61.
    PubMed     Abstract available
    
    
    
82. WARREN RB, Basey V, Lynam A, Curtis C, et al
    The risk of venous thromboembolism in atopic dermatitis: A matched cohort analysis in UK primary care.
    Br J Dermatol. 2023 Jul 7:ljad212. doi: 10.1093.
    PubMed     Abstract available
    
    
    
83. CONNOLLY A, Walsh S, Philippidou M, Salisbury J, et al
    Acute hepatic failure in trimethoprim-induced drug rash with eosinophilia and systemic symptoms (DRESS).
    Br J Dermatol. 2023;189:140-141.
    PubMed    
    
    
    
84. ERTUS C, Scailteux LM, Lescoat A, Berthe P, et al
    Major adverse cardiovascular events in patients treated with oral Janus kinase inhibitors for atopic dermatitis: a systematic review and meta-analysis.
    Br J Dermatol. 2023 Jul 6:ljad229. doi: 10.1093.
    PubMed     Abstract available
    
    
    
85. OLLECH A, Lefferdink R, Sheth A, Blumstein A, et al
    Systemic Immunosuppressive Therapies for Children with Refractory Atopic Dermatitis: A Large Real-Life Cohort Study.
    Br J Dermatol. 2023 Jul 5:ljad222. doi: 10.1093.
    PubMed    
    
    
    
86. HONG CH, Lee CH
    A nationwide UK cohort study reveals an association between atopic dermatitis and venous thromboembolism.
    Br J Dermatol. 2023 Jul 5:ljad221. doi: 10.1093.
    PubMed    
    
    
    June 2023
87. RUTH E, Heraghty F, Flynn N, McGlynn T, et al
    No evidence of isotretinoin sensitisation in peanut allergic children - a cross-sectional study.
    Br J Dermatol. 2023 Jun 28:ljad214. doi: 10.1093.
    PubMed    
    
    
    
88. LUO M, Zhu C, Lin J, Lin L, et al
    Bidirectional Mendelian randomization analysis did not indicate a causal relationship between atopic dermatitis and COVID-19.
    Br J Dermatol. 2023 Jun 27:ljad208. doi: 10.1093.
    PubMed    
    
    
    
89. OGAWA-MOMOHARA M, Muro Y, Murase C, Taki T, et al
    Allergen-specific IgG4 increase in atopic dermatitis with long-term dupilumab use.
    Br J Dermatol. 2023 Jun 27:ljad207. doi: 10.1093.
    PubMed    
    
    
    
90. HAN JH, Ju HJ, Kang H, Lee JH, et al
    Autoimmune, Inflammatory, Allergic, and Neuropsychiatric Outcomes of Offspring Born to Mothers with Vitiligo: A Nationwide Population-based Birth Cohort Study of Korea.
    Br J Dermatol. 2023 Jun 19:ljad196. doi: 10.1093.
    PubMed    
    
    
    May 2023
91. 
    Results from 1 year of treatment with lebrikizumab for atopic dermatitis.
    Br J Dermatol. 2023;188:e43.
    PubMed    
    
    
    
92. 
    Atopic eczema: palmar patterns associated with filaggrin variants, disease severity and barrier function in a South Asian population.
    Br J Dermatol. 2023;188:e46.
    PubMed    
    
    
    
93. 
    Atopic dermatitis across the globe: differences in prevalence and access to treatments.
    Br J Dermatol. 2023;188:e42.
    PubMed    
    
    
    
94. THOMAS BR, Tan XL, Van Duijvenboden S, Hogan SC, et al
    Deep palmar phenotyping in atopic eczema: patterns associated with filaggrin variants, disease severity and barrier function in a South Asian population.
    Br J Dermatol. 2023;188:785-792.
    PubMed     Abstract available
    
    
    
95. HIJNEN D, Olydam J
    Prediction of response to dupilumab treatment.
    Br J Dermatol. 2023;188:e41.
    PubMed    
    
    
    
96. 
    Correction to: 319 Effects of omega-3 fatty acid supplementation on atopic dermatitis.
    Br J Dermatol. 2023 May 22:ljad154. doi: 10.1093.
    PubMed    
    
    
    
97. SPEKHORST LS, Boesjes CM, Loman L, Zuithoff NPA, et al
    Successful tapering of dupilumab in atopic dermatitis patients with low disease activity: a large pragmatic daily practice study from the BioDay registry.
    Br J Dermatol. 2023 May 13:ljad159. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2023
98. FLOHR C, Irvine AD, Cork MJ, Simpson EL, et al
    Dupilumab improves patient-reported symptoms and health-related quality of life in children aged 6-11 years with severe atopic dermatitis.
    Br J Dermatol. 2023 Apr 30:ljad124. doi: 10.1093.
    PubMed    
    
    
    
99. ARENTS BWM
    Intriguing findings on lebrikizumab for treating moderate-to-severe atopic dermatitis.
    Br J Dermatol. 2023 Apr 24:ljad068. doi: 10.1093.
    PubMed    
    
    
    
100. 
     Serum biomarker analysis to identify subtypes of atopic dermatitis in China and to help with predicting the effectiveness of treatment with dupilumab.
     Br J Dermatol. 2023;188:e37.
     PubMed    
     
     
     
101. BEN ABDALLAH H, Johansen C
     Transmembrane protein 232 (TMEM232) regulates inflammation in experimental models of atopic dermatitis.
     Br J Dermatol. 2023 Apr 17:ljad127. doi: 10.1093.
     PubMed    
     
     
     
102. QUAADE AS, Wang X, Solberg JBK, Ulrich NH, et al
     Circulating biomarkers are associated with disease severity of chronic hand eczema and atopic dermatitis.
     Br J Dermatol. 2023 Apr 13:ljad110. doi: 10.1093.
     PubMed     Abstract available
     
     
     
103. VITTRUP I
     Malignancy risk in atopic dermatitis: heterogenous effects and perspectives.
     Br J Dermatol. 2023 Apr 11:ljad119. doi: 10.1093.
     PubMed    
     
     
     March 2023
104. TORRELO A, Rewerska B, Galimberti M, Paller A, et al
     Efficacy and safety of baricitinib in combination with topical corticosteroids in pediatric patients with moderate-to-severe atopic dermatitis with inadequate response to topical corticosteroids: results from a phase 3, randomized, double-blind, place
     Br J Dermatol. 2023 Mar 31:ljad096. doi: 10.1093.
     PubMed     Abstract available
     
     
     
105. BLAUVELT A, Thyssen JP, Guttman-Yassky E, Bieber T, et al
     Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials.
     Br J Dermatol. 2023 Mar 30:ljad022. doi: 10.1093.
     PubMed     Abstract available
     
     
     
106. 
     Factors associated with mental illness in adults with atopic eczema or psoriasis.
     Br J Dermatol. 2023;188:e27.
     PubMed    
     
     
     
107. 
     Quality of life of Bangladeshi children and young adults with atopic eczema and their families in East London.
     Br J Dermatol. 2023;188:e33.
     PubMed    
     
     
     
108. TAWFIK SS, Thomas BR, Kelsell DP, Grigg J, et al
     Dermatology Quality of Life Index scores in Bangladeshi patients with atopic eczema and their families in East London.
     Br J Dermatol. 2023;188:524-532.
     PubMed     Abstract available
     
     
     
109. MAGIN P, Fisher K
     Online behavioural interventions for children and young people with atopic eczema: refining the way forward.
     Br J Dermatol. 2023;188:453.
     PubMed    
     
     
     
110. VANCE TM, Li T, Cho E, Drucker AM, et al
     Prenatal antibiotic use and subsequent risk of atopic eczema.
     Br J Dermatol. 2023;188:561-563.
     PubMed    
     
     
     
111. CAPOZZA K
     Lost in translation: understanding the experience of atopic eczema among non-English-speaking families.
     Br J Dermatol. 2023;188:456-457.
     PubMed    
     
     
     
112. SINIKUMPU SP, Jokelainen J, Huilaja L
     The association between atopic dermatitis and acne: a retrospective Finnish nationwide registry study.
     Br J Dermatol. 2023 Mar 22:ljad086. doi: 10.1093.
     PubMed    
     
     
     
113. RAGAMIN A, Tupker RA, de Graaf M, Rustemeyer T, et al
     Investigator Global Assessment for impetiginization in Atopic Dermatitis (IGA impetiginization): Development and initial reliability testing.
     Br J Dermatol. 2023 Mar 22:ljad085. doi: 10.1093.
     PubMed    
     
     
     
114. PATHMARAJAH P, Corso R, Salam A, Shah G, et al
     Neutropenia in patients on dupilumab for atopic dermatitis: a case series and review of trial data.
     Br J Dermatol. 2023 Mar 17:ljad038. doi: 10.1093.
     PubMed    
     
     
     
115. HAN J, Cai X, Qin S, Zhang Z, et al
     TMEM232 Promotes the Inflammatory Response in Atopic Dermatitis via NF-kappaB and STAT3 Signaling Pathways.
     Br J Dermatol. 2023 Mar 17:ljad078. doi: 10.1093.
     PubMed     Abstract available
     
     
     
116. MOSAM A, Todd G
     Global epidemiology and disparities in atopic dermatitis.
     Br J Dermatol. 2023 Mar 7:ljad042. doi: 10.1093.
     PubMed     Abstract available
     
     
     
117. DRUCKER AM
     Atopic dermatitis in 2023 and beyond.
     Br J Dermatol. 2023 Mar 2:ljad053. doi: 10.1093.
     PubMed    
     
     
     February 2023
118. 
     Atopic dermatitis and school performance in children and young adults.
     Br J Dermatol. 2023;188:e21.
     PubMed    
     
     
     
119. SUN X, Sheng A, Xu AE
     Successful treatment of vitiligo with crisaborole ointment: a report of two cases.
     Br J Dermatol. 2023;188:436-437.
     PubMed    
     
     
     
120. VON KOBYLETZKI L
     Which patients with atopic eczema and psoriasis develop depression, anxiety, and severe mental illness: is the evidence clear?
     Br J Dermatol. 2023 Feb 15:ljad009. doi: 10.1093.
     PubMed    
     
     
     
121. 
     Small particles of cobalt cause eczema in people with allergies.
     Br J Dermatol. 2023;188:e20.
     PubMed    
     
     
     
122. 
     Patients successfully treated with baricitinib for atopic dermatitis: what happens if they lower their dose or stop treatment?
     Br J Dermatol. 2023;188:e14.
     PubMed    
     
     
     
123. REICH K, Simpson E, Wollenberg A, Bissonnette R, et al
     Efficacy of downtitration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomized substudy from the long-term extension study BREEZE-AD3.
     Br J Dermatol. 2023;188:208-217.
     PubMed     Abstract available
     
     
     
124. GILL K, Xu J, Kozera E, Stewart T, et al
     Strongyloides screening prior to dupilumab therapy in atopic dermatitis: a retrospective cohort study evaluating screening utility.
     Br J Dermatol. 2023;188:294-295.
     PubMed    
     
     
     
125. SYMANZIK C, John SM
     Occupational exposure to cobalt nanoparticles: potential implications on risk assessment and preventive measures.
     Br J Dermatol. 2023;188:161-162.
     PubMed    
     
     
     
126. WU Y, Gu C, Wang S, Yin H, et al
     Serum biomarker-based endotypes of atopic dermatitis in China and prediction for efficacy of dupilumab.
     Br J Dermatol. 2023 Feb 9:ljad032. doi: 10.1093.
     PubMed     Abstract available
     
     
     January 2023
127. MCSWEENEY SM, Bintcliffe K, Fassihi H, Sarkany R, et al
     Local cutaneous refractoriness to sun exposure following omalizumab injections in solar urticaria.
     Br J Dermatol. 2023 Jan 27:ljad012. doi: 10.1093.
     PubMed    
     
     
     
128. SIMPSON RC
     Safety of tralokinumab in atopic dermatitis.
     Br J Dermatol. 2023 Jan 26:ljad007. doi: 10.1093.
     PubMed    
     
     
     
129. KOGAME T, Yonekura S, Lovato P, Hirata M, et al
     Interleukin-13 inhibition by tralokinumab reduces inducible T-cell costimulator-positive innate lymphoid cells in skin lesions of atopic dermatitis.
     Br J Dermatol. 2023;188:146-148.
     PubMed    
     
     
     
130. ZHANG J, Schuttelaar MLA
     Water and adult eczema: the hard truth?
     Br J Dermatol. 2023;188:e1.
     PubMed    
     
     
     
131. VINCENT R, Ormerod E, Gollins CE, Rai N, et al
     Semi-virtual patch testing: the future?
     Br J Dermatol. 2023;188:137-139.
     PubMed    
     
     
     
132. ARDERN-JONES MR, Buchanan EE, Njungu S, O'Driscoll D, et al
     Successful Dose Reduction of Dupilumab in Atopic Dermatitis.
     Br J Dermatol. 2023 Jan 20:ljad011. doi: 10.1093.
     PubMed    
     
     
     
133. YEW YW, Apfelbacher CJ
     Validation of novel diagnostic criteria for atopic dermatitis in an adult and elderly Chinese population.
     Br J Dermatol. 2023 Jan 5:ljac143. doi: 10.1093.
     PubMed    
     
     
     December 2022
134. ADESANYA EI, Matthewman J, Schonmann Y, Hayes JF, et al
     Factors associated with depression, anxiety and severe mental illness among adults with atopic eczema or psoriasis: a systematic review and meta-analysis.
     Br J Dermatol. 2022 Dec 19:ljac132. doi: 10.1093.
     PubMed     Abstract available
     
     
     
135. YUE W, Cheng D, Sun Z, Shen Y, et al
     Validation of diagnostic criteria for atopic dermatitis and proposal of novel diagnostic criteria for adult and elderly Chinese populations: a multicentre, prospective, clinical setting-based study.
     Br J Dermatol. 2022 Dec 12:ljac097. doi: 10.1093.
     PubMed     Abstract available
     
     
     
136. FLOHR C
     How we treat atopic dermatitis now and how that will change over the next 5 years.
     Br J Dermatol. 2022 Dec 7:ljac116. doi: 10.1093.
     PubMed     Abstract available
     
     
     
137. GABES M, Ragamin A, Baker A, Kann G, et al
     Content validity of the Recap of atopic eczema (RECAP) instrument in Dutch, English and German to measure eczema control in young people with atopic eczema: a cognitive interview study.
     Br J Dermatol. 2022;187:919-926.
     PubMed     Abstract available
     
     
     November 2022
138. HU C, Jansen PW
     Do adolescents with atopic dermatitis have lower cognitive function and school performance than their peers without atopic dermatitis?
     Br J Dermatol. 2022 Nov 29:ljac105. doi: 10.1093.
     PubMed    
     
     
     
139. ABUABARA K, Langan SM
     Atopic dermatitis across the life course.
     Br J Dermatol. 2022 Nov 18:ljac072. doi: 10.1093.
     PubMed     Abstract available
     
     
     
140. TRIER AM, Kim BS
     Insights into atopic dermatitis pathogenesis lead to newly approved systemic therapies.
     Br J Dermatol. 2022 Nov 18:ljac016. doi: 10.1093.
     PubMed     Abstract available
     
     
     
141. WEISSHAAR E, Bentz P, Haufe E, Heinrich L, et al
     Itching and treatments in atopic dermatitis (AD): results from the German AD registry TREATgermany.
     Br J Dermatol. 2022 Nov 17:ljac070. doi: 10.1093.
     PubMed    
     
     
     
142. CLAYTON K, Holbrook DJ, Vallejo A, Porter G, et al
     Skin programming of inflammatory responses to Staphylococcus aureus is compartmentalized according to epidermal keratinocyte differentiation status.
     Br J Dermatol. 2022 Nov 17:ljac088. doi: 10.1093.
     PubMed     Abstract available
     
     
     
143. VITTRUP I, Andersen YMF, Skov L, Wu JJ, et al
     The association between atopic dermatitis, cognitive function and school performance in children and young adults.
     Br J Dermatol. 2022 Nov 3:ljac058. doi: 10.1093.
     PubMed     Abstract available
     
     
     
144. ORCHARD D
     Preventing atopic eczema: vitamin D supplementation another piece of the puzzle?
     Br J Dermatol. 2022;187:630-631.
     PubMed    
     
     
     
145. EL-HEIS S, D'Angelo S, Curtis EM, Healy E, et al
     Maternal antenatal vitamin D supplementation and offspring risk of atopic eczema in the first 4 years of life: evidence from a randomized controlled trial.
     Br J Dermatol. 2022;187:659-666.
     PubMed     Abstract available
     
     
     October 2022
146. MIDANDER K, Werner P, Isaksson M, Wisgrill L, et al
     Cobalt nanoparticles cause allergic contact dermatitis in humans.
     Br J Dermatol. 2022 Oct 28:ljac043. doi: 10.1093.
     PubMed     Abstract available
     
     
     
147. TURNER CT, Zeglinski MR, Boivin W, Zhao H, et al
     Granzyme K contributes to endothelial microvascular damage and leakage during skin inflammation.
     Br J Dermatol. 2022 Oct 23:ljac017. doi: 10.1093.
     PubMed     Abstract available
     
     
     
148. CUCKA B, Biglione B, Zhou L, Phillips EJ, et al
     Drug reaction with eosinophilia and systemic symptoms in patients hospitalized with COVID-19: a case series from a large US healthcare system.
     Br J Dermatol. 2022;187:619-622.
     PubMed    
     
     
     September 2022
149. SIMPSON EL, Merola JF, Silverberg JI, Reich K, et al
     Safety of Tralokinumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis: Pooled Analysis of Five Randomized, Double-blind, Placebo-controlled Phase 2 and Phase 3 Trials.
     Br J Dermatol. 2022 Sep 9. doi: 10.1111/bjd.21867.
     PubMed     Abstract available
     
     
     
150. KIM RW, Barta K, Begolka WS, Capozza K, et al
     The quantitative impact of atopic dermatitis on caregivers across multiple life domains.
     Br J Dermatol. 2022 Sep 3. doi: 10.1111/bjd.21855.
     PubMed    
     
     
     
151. 
     Revolutionizing Atopic Dermatitis, 9-11 April 2022.
     Br J Dermatol. 2022;187:e80-e155.
     PubMed    
     
     
     August 2022
152. LANDIS MN, Arya M, Smith S, Draelos Z, et al
     Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomised, double-blind, vehicle-controlled, dose-ranging, and parallel-group study.
     Br J Dermatol. 2022 Aug 20. doi: 10.1111/bjd.21826.
     PubMed     Abstract available
     
     
     
153. KIM RW, Barta K, Begolka WS, Capozza K, et al
     Qualitative analysis of the impact of atopic dermatitis on caregivers and the quantitative impact of atopic dermatitis on caregivers across multiple life domains.
     Br J Dermatol. 2022 Aug 16. doi: 10.1111/bjd.21828.
     PubMed    
     
     
     
154. CHRISTIANSEN AG, Carstensen O, Sommerlund M, Clausen PA, et al
     Prevalence of skin sensitisation and dermatitis among epoxy-exposed workers in the wind turbine industry.
     Br J Dermatol. 2022 Aug 16. doi: 10.1111/bjd.21830.
     PubMed     Abstract available
     
     
     
155. MORGAN CL, Thomas M, Stander S, Jabbar-Lopez ZK, et al
     Epidemiology of prurigo nodularis in England: a retrospective database analysis.
     Br J Dermatol. 2022;187:188-195.
     PubMed     Abstract available
     
     
     July 2022
156. YANG N, Chen L, Shao J, Jiang F, et al
     Dupilumab with concomitant JAK inhibitor: A novel treatment strategy for atopic dermatitis with poor response to dupilumab.
     Br J Dermatol. 2022 Jul 13. doi: 10.1111/bjd.21776.
     PubMed    
     
     
     
157. WORM M, Thyssen JP, Schliemann S, Bauer A, et al
     The pan-JAK inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16-week randomized phase IIb trial.
     Br J Dermatol. 2022;187:42-51.
     PubMed     Abstract available
     
     
     June 2022
158. SCHNEEWEISS MC, Kirchgesner J, Wyss R, Jin Y, et al
     Occurrence of inflammatory bowel disease in patients with chronic inflammatory skin diseases: a cohort study.
     Br J Dermatol. 2022 Jun 19. doi: 10.1111/bjd.21704.
     PubMed     Abstract available
     
     
     
159. BETTUZZI T, Hua C, Diaz E, Colin A, et al
     Epidermal necrolysis: characterization of different phenotypes using an unsupervised clustering analysis.
     Br J Dermatol. 2022;186:1037-1039.
     PubMed    
     
     
     May 2022
160. CHEN CW, Wei JC
     Response to 'Validation of generalized drug-related rash diagnoses using International Classification of Diseases 9th and 10th Revision codes'.
     Br J Dermatol. 2022;186:910-911.
     PubMed    
     
     
     
161. GOLDENBERG M, Krishna SG, Milani-Nejad N, Trinidad JC, et al
     Response to: 'Validation of generalized drug-related rash diagnoses using International Classification of Diseases 9(th) and 10(th) Revision codes': reply from the authors.
     Br J Dermatol. 2022;186:911.
     PubMed    
     
     
     April 2022
162. BIEBER T, Reich K, Paul C, Tsunemi Y, et al
     Efficacy and Safety of Baricitinib in Combination With Topical Corticosteroids in Patients With Moderate-to-Severe Atopic Dermatitis With Inadequate Response, Intolerance, or Contraindication to Cyclosporine: Results From a Randomized, Placebo-Control
     Br J Dermatol. 2022 Apr 28. doi: 10.1111/bjd.21630.
     PubMed     Abstract available
     
     
     
163. LAQUER V, Parra V, Lacour JP, Takahashi H, et al
     IL-33 antibody failed to demonstrate benefit in a phase 2 double-blind, randomised placebo-controlled study in adult patients with moderate-to-severe atopic dermatitis.
     Br J Dermatol. 2022 Apr 28. doi: 10.1111/bjd.21631.
     PubMed    
     
     
     
164. JENDOUBI F, Shourik J, Seneschal J, Giordano-Labadie F, et al
     Longer Dupilumab Dosing Intervals in Adult Patients with Atopic Dermatitis: Experience from a French Multicentre Retrospective Cohort Study.
     Br J Dermatol. 2022 Apr 28. doi: 10.1111/bjd.21628.
     PubMed    
     
     
     
165. SIMPSON EL, Bissonnette R, Paller AS, King B, et al
     The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): A Clinical Outcome Measure for the Severity of Atopic Dermatitis.
     Br J Dermatol. 2022 Apr 20. doi: 10.1111/bjd.21615.
     PubMed     Abstract available
     
     
     
166. 
     Revolutionizing Atopic Dermatitis, 11-13 December 2021.
     Br J Dermatol. 2022;186:e135-e185.
     PubMed    
     
     
     
167. BARBAROT S
     Targeting the itch-scratch vicious circle in atopic eczema.
     Br J Dermatol. 2022;186:608.
     PubMed    
     
     
     March 2022
168. JACOBY TV, Otto TS, Asdourian MS, Shah N, et al
     Association of preexisting drug allergies with cutaneous immune related adverse events among patients on immune checkpoint inhibitor therapy.
     Br J Dermatol. 2022 Mar 15. doi: 10.1111/bjd.21243.
     PubMed    
     
     
     
169. NOVAK N, Cabanillas B
     Herpesvirus, serious and opportunistic infections associated with atopic dermatitis.
     Br J Dermatol. 2022 Mar 6. doi: 10.1111/bjd.20982.
     PubMed    
     
     
     
170. SABROE RA, Lawlor F, Grattan CEH, Ardern-Jones MR, et al
     British Association of Dermatologists guidelines for the management of people with chronic urticaria 2021.
     Br J Dermatol. 2022;186:398-413.
     PubMed    
     
     
     
171. GOLDENBERG M, Amigo M, Krishna SG, Milani-Nejad N, et al
     Validation of generalized drug-related rash diagnoses using International Classification of Diseases 9th and 10th Revision codes.
     Br J Dermatol. 2022;186:583-585.
     PubMed    
     
     
     February 2022
172. NGUYEN R
     Ocular conjunctivitis in biological therapies for atopic dermatitis.
     Br J Dermatol. 2022 Feb 16. doi: 10.1111/bjd.20945.
     PubMed    
     
     
     
173. FUTAMURA M
     Easy assessment tool for disease severity of atopic dermatitis in clinical practice.
     Br J Dermatol. 2022 Feb 6. doi: 10.1111/bjd.20951.
     PubMed    
     
     
     
174. MARGOLIS DJ
     Atopic dermatitis: filaggrin and skin barrier dysfunction.
     Br J Dermatol. 2022 Feb 6. doi: 10.1111/bjd.20946.
     PubMed    
     
     
     
175. GLEESON D, Cliff S, Das M
     Eruptive keratoacanthomas associated with dupilumab therapy.
     Br J Dermatol. 2022;186:376-377.
     PubMed     Abstract available
     
     
     
176. GAUDIN O, Milpied B, Papouin B, Hue S, et al
     Lupus erythematosus and epidermal necrolysis: a case series of 16 patients.
     Br J Dermatol. 2022;186:372-374.
     PubMed    
     
     
     January 2022
177. PAKHCHANIAN H, Raiker R, Wolf M, Trotter SC, et al
     Examining the Risk of Breakthrough Infection and COVID-19 Vaccination Safety in Atopic Dermatitis Patients.
     Br J Dermatol. 2022 Jan 27. doi: 10.1111/bjd.21038.
     PubMed    
     
     
     
178. PENNY CL, Quow K, Rundle CW, Al-Rohil RN, et al
     Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin.
     Br J Dermatol. 2022 Jan 19. doi: 10.1111/bjd.21022.
     PubMed    
     
     
     
179. EBATA T
     Dose flexibility of oral Janus kinase inhibitors for long-term control of atopic dermatitis.
     Br J Dermatol. 2022 Jan 19:ljac082. doi: 10.1093.
     PubMed    
     
     
     
180. YOSIPOVITCH G, Papp K, Forman S, Han G, et al
     The contribution of itch and skin severity improvements to the Dermatology Life Quality Index in patients with atopic dermatitis in baricitinib phase 3 trials.
     Br J Dermatol. 2022 Jan 18. doi: 10.1111/bjd.21015.
     PubMed    
     
     
     
181. KOZERA E, Stewart T, Gill K, De La Vega MA, et al
     Dupilumab Associated Head and Neck Dermatitis is Associated with Elevated Pre-Treatment Serum Malassezia-Specific Immunoglobulin E: A Multicenter, Prospective Cohort Study.
     Br J Dermatol. 2022 Jan 18. doi: 10.1111/bjd.21019.
     PubMed    
     
     
     
182. KEZIC S, McAleer MA, Jakasa I, Goorden SMI, et al
     Children with atopic dermatitis show increased activity of beta- glucocerebrosidase and stratum corneum levels of glucosylcholesterol that are strongly related to local cytokine milieu.
     Br J Dermatol. 2022 Jan 7. doi: 10.1111/bjd.20979.
     PubMed     Abstract available
     
     
     
183. ARENTS BWM, Zuuren EJV, Vermeulen S, Schoones JW, et al
     Global Guidelines in Dermatology Mapping Project (GUIDEMAP) - a systematic review of atopic dermatitis clinical practice guidelines: are they clear, unbiased, trustworthy and evidence based (CUTE)?
     Br J Dermatol. 2022 Jan 4. doi: 10.1111/bjd.20972.
     PubMed     Abstract available
     
     
     November 2021
184. SINIKUMPU SP, Huilaja L
     Challenges of multidimensional atopic dermatitis.
     Br J Dermatol. 2021 Nov 24. doi: 10.1111/bjd.20874.
     PubMed    
     
     
     
185. DEZOTEUX F, El Mesbahi S, Tedbirt B, Grosjean J, et al
     Immunomodulatory or/and immunosuppressive drugs should not avoid skin test for the assessment of drug allergy.
     Br J Dermatol. 2021 Nov 22. doi: 10.1111/bjd.20901.
     PubMed     Abstract available
     
     
     
186. MARNIQUET ME, Seneschal J, Darrigade AS, Staumont-Salle D, et al
     Reasons for Discontinuation of dupilumab in Adult Atopic Dermatitis in Clinical Practice.
     Br J Dermatol. 2021 Nov 8. doi: 10.1111/bjd.20883.
     PubMed     Abstract available
     
     
     
187. WAN J, Shin DB, Syed MN, Abuabara K, et al
     Risk of herpesvirus, serious, and opportunistic infections in atopic dermatitis: a population-based cohort study.
     Br J Dermatol. 2021 Nov 8. doi: 10.1111/bjd.20887.
     PubMed     Abstract available
     
     
     
188. CHIESA Z
     How important is it to distinguish between eczema and atopic dermatitis in infants? Implications for prognosis and epidemiological research.
     Br J Dermatol. 2021 Nov 2. doi: 10.1111/bjd.20814.
     PubMed    
     
     
     
189. BEN ABDALLAH H, Vestergaard C
     Atopic dermatitis, hypertension and cardiovascular disease.
     Br J Dermatol. 2021 Nov 2. doi: 10.1111/bjd.20802.
     PubMed    
     
     
     
190. PALLER AS, Tan JKL, Bagel J, Rossi AB, et al
     IGAxBSA composite for assessing disease severity and response in patients with atopic dermatitis.
     Br J Dermatol. 2021 Nov 2. doi: 10.1111/bjd.20872.
     PubMed     Abstract available
     
     
     
191. KABASHIMA K, Matsumura T, Komazaki H, Kawashima M, et al
     Nemolizumab plus topical agents in patients with atopic dermatitis and moderate-to-severe pruritus provide improvement in pruritus and signs of atopic dermatitis for up to 68 weeks: results from two phase III, long-term studies.
     Br J Dermatol. 2021 Nov 2. doi: 10.1111/bjd.20873.
     PubMed     Abstract available
     
     
     October 2021
192. HOYER A, Rehbinder EM, Fardig M, Asad S, et al
     Filaggrin mutations in relation to skin barrier and atopic dermatitis in early infancy.
     Br J Dermatol. 2021 Oct 26. doi: 10.1111/bjd.20831.
     PubMed     Abstract available
     
     
     
193. GUTERMUTH J, Pink AE, Worm M, Soldbro L, et al
     Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of cyclosporine A: a placebo-controlled, randomized, Phase 3 clinical trial (ECZTRA 7).
     Br J Dermatol. 2021 Oct 26. doi: 10.1111/bjd.20832.
     PubMed     Abstract available
     
     
     
194. WOLLENBERG A, Beck LA, de Bruin Weller M, Simpson EL, et al
     Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials.
     Br J Dermatol. 2021 Oct 12. doi: 10.1111/bjd.20810.
     PubMed     Abstract available
     
     
     
195. PUELLES J, Fofana F, Rodriguez D, Silverberg JI, et al
     Psychometric Validation and Responder Definition of Sleep Disturbance Numerical Rating Scale in Moderate-To-Severe Atopic Dermatitis.
     Br J Dermatol. 2021 Oct 5. doi: 10.1111/bjd.20783.
     PubMed     Abstract available
     
     
     
196. BERMINGHAM WH, Ardern-Jones MR, Huissoon AP, Krishna MT, et al
     Forewarned is forearmed: chronic spontaneous urticaria as a potential risk to effective SARS-CoV-2 vaccine uptake and global public health.
     Br J Dermatol. 2021;185:838-839.
     PubMed    
     
     
     
197. FLORES C
     Decoding the pharmacogenetics of nonsteroidal anti-inflammatory drug hypersensitivity.
     Br J Dermatol. 2021;185:697-698.
     PubMed    
     
     
     
198. STANDL M
     Addressing the causality of the association of atopic dermatitis with depression and anxiety using Mendelian randomization.
     Br J Dermatol. 2021;185:694-695.
     PubMed    
     
     
     
199. JURADO-ESCOBAR R, Dona I, Perkins JR, Laguna JJ, et al
     Polymorphisms in eicosanoid-related biosynthesis enzymes associated with acute urticaria/angioedema induced by nonsteroidal anti-inflammatory drug hypersensitivity.
     Br J Dermatol. 2021;185:815-824.
     PubMed     Abstract available
     
     
     
200. BAURECHT H, Welker C, Baumeister SE, Weidnger S, et al
     Relationship between atopic dermatitis, depression and anxiety: a two-sample Mendelian randomization study.
     Br J Dermatol. 2021;185:781-786.
     PubMed     Abstract available
     
     
     September 2021
201. NAKAMURA T, Haider S, Fontanella S, Murray CS, et al
     Modelling trajectories of parentally reported and physician-confirmed atopic dermatitis in a birth cohort study.
     Br J Dermatol. 2021 Sep 26. doi: 10.1111/bjd.20767.
     PubMed     Abstract available
     
     
     
202. FORSYTH JR, Russell E, McPherson T
     A retrospective case series of paediatric Stevens-Johnson syndrome and toxic epidermal necrolysis: evaluation of practice using the British Association of Dermatology's National Guidelines for children and young people.
     Br J Dermatol. 2021 Sep 4. doi: 10.1111/bjd.20741.
     PubMed     Abstract available
     
     
     August 2021
203. JACOBY TV, Chang MS, Thompson LL, Foreman RK, et al
     Histopathologically-confirmed lichenoid eruptions from immune checkpoint inhibitor therapy: A retrospective cohort analysis.
     Br J Dermatol. 2021 Aug 10. doi: 10.1111/bjd.20698.
     PubMed     Abstract available
     
     
     March 2021
204. SCHONMANN Y, Mansfield KE, Mulick A, Roberts A, et al
     Inflammatory Skin Diseases and the Risk of Chronic Kidney Disease - Population-Based Case-control and Cohort analyses.
     Br J Dermatol. 2021 Mar 17. doi: 10.1111/bjd.20067.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Hypersensitivity Reaction is free of charge.